What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders
Atai Life Sciences (NASDAQ: ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix.
Atai Life Launches Depression-Focused Firm
Atai Life Sciences NV (NASDAQ:ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix…
Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery
Photo by CDC on Unsplash
Atai Life Sciences Announces The Launch Of PsyProtix, To Develop A Precision Psychiatry Approach For Treatment-resistant Depression
atai Life Sciences (NASDAQ:ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 4)
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF
On Thursday, AdvisorShares launched the country’s first actively managed ETF covering the psychedelics sector.
Can Ketamine For Depression Be Improved? New Study Will Look Into Ketamine Analog Arketamine
Perception Neuroscience, an Atai Life Sciences (NASDAQ: ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate.
